Valuation: Ocugen, Inc.

Market Cap 349M 304M 287M 261M 488M 33.48B 491M 3.43B 1.33B 17.03B 1.31B 1.28B 54.79B P/E 2026 *
-4.08x
P/E 2027 * -3.79x
Enterprise Value 349M 304M 287M 261M 488M 33.48B 491M 3.43B 1.33B 17.03B 1.31B 1.28B 54.79B EV / Sales 2026 *
73.4x
EV / Sales 2027 * 140x
Free-Float
98.42%
Yield 2026 *
-
Yield 2027 * -
1 week+4.59%
Current month-18.52%
1 month-21.06%
3 months-16.27%
6 months-54.40%
Current year-28.55%
1 week 0.84
Extreme 0.84
0.93
1 month 0.84
Extreme 0.84
1.28
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.82%+0.57%-21.26%+146.35% 349M
+0.11%+1.98%-0.04%+9.69% 46.18B
-1.12%+3.54%+42.71%+25.84% 44.35B
-3.04%-6.10%+335.86%+501.23% 42.21B
-0.74%+2.64%+5.61%+75.14% 40.19B
-0.50%-0.77%+11.86%+40.41% 29.83B
-0.46%+5.00%+23.00%+118.70% 17.17B
-0.97%-9.38% - - 15.7B
-0.57%+7.78%+21.76%+38.08% 15.32B
-3.28%-0.95%-6.34%-37.29% 13.09B
Average -1.17%+1.67%+45.91%+102.02% 29.34B
Weighted average by Cap. -1.11%+1.63%+69.51%+117.26%

Financials

2026 *2027 *
Net sales 4.76M 4.14M 3.91M 3.55M 6.65M 456M 6.68M 46.76M 18.06M 232M 17.87M 17.47M 746M 2.5M 2.18M 2.05M 1.87M 3.5M 240M 3.51M 24.57M 9.49M 122M 9.39M 9.18M 392M
Net income -87.21M -75.93M -71.67M -65.11M -122M -8.36B -123M -857M -331M -4.25B -328M -320M -13.68B -97.94M -85.27M -80.49M -73.13M -137M -9.39B -138M -963M -372M -4.78B -368M -360M -15.36B
Net Debt - -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
18/09/26 EUR 0.9110 +2.82%
17/09/26 EUR 0.8860 +1.84%
16/09/26 EUR 0.8700 +1.05%
15/09/26 EUR 0.8610 -5.07%
14/09/26 EUR 0.9070 +4.13%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.030USD
Average target price
12.08USD
Spread / Average Target
+1,073.14%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!